Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Knight Therapeutics Inc T.GUD

Alternate Symbol(s):  KHTRF

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company’s principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.


TSX:GUD - Post by User

Comment by gudisgoodon Jan 07, 2024 6:49am
264 Views
Post# 35814389

RE:Jan 3rd Share Repurchase… 2,999,497

RE:Jan 3rd Share Repurchase… 2,999,497We will still see growth from the current portfolio (plus the couple of launches) this year. Hopefully the Ambisome orders continue coming in as well. And for 2025, there are many launches scheduled. It's also possible, if not likely, that we add to our current portfolio or pipeline from now until 2025.

Meanwhile the buybacks have been aggressive at lower levels. I hope they stay that way. In my humble opinion, the company is still really, really undervalued, although less-so than a while ago. For an opportunistic company like GUD, the best place for the stock price to be is really low or really high -- so I would prefer if the price stayed really low until they run out of ammo for buybacks.

But... the latest report looked good, it's all moving the right way, new opportunities will come along while the current operations continue to perform. GUD generates a lot of cash and has a strong balance sheet. Canada, Mexico, some CNS products maybe to go along with Exelon? When they find these, they will do it.

It's looking pretty good, I would say.
<< Previous
Bullboard Posts
Next >>